nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—P-Glycoprotein Inhibitors—Cyclosporine—focal segmental glomerulosclerosis	0.808	1	CiPCiCtD
Crizotinib—INSRR—kidney—focal segmental glomerulosclerosis	0.00311	0.057	CbGeAlD
Crizotinib—Acute respiratory distress syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.0021	0.117	CcSEcCtD
Crizotinib—TIE1—endothelium—focal segmental glomerulosclerosis	0.00198	0.0364	CbGeAlD
Crizotinib—Polyneuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00168	0.0935	CcSEcCtD
Crizotinib—RIPK2—endothelium—focal segmental glomerulosclerosis	0.00163	0.0299	CbGeAlD
Crizotinib—PTK2—endothelium—focal segmental glomerulosclerosis	0.00151	0.0277	CbGeAlD
Crizotinib—PRKD1—nephron tubule—focal segmental glomerulosclerosis	0.00143	0.0262	CbGeAlD
Crizotinib—NEK9—kidney—focal segmental glomerulosclerosis	0.00137	0.0253	CbGeAlD
Crizotinib—EPHB4—endothelium—focal segmental glomerulosclerosis	0.00137	0.0252	CbGeAlD
Crizotinib—TEK—endothelium—focal segmental glomerulosclerosis	0.00132	0.0242	CbGeAlD
Crizotinib—PRKD1—kidney—focal segmental glomerulosclerosis	0.00125	0.023	CbGeAlD
Crizotinib—PRKD3—kidney—focal segmental glomerulosclerosis	0.0012	0.0221	CbGeAlD
Crizotinib—SRC—endothelium—focal segmental glomerulosclerosis	0.00117	0.0215	CbGeAlD
Crizotinib—DSTYK—cortex of kidney—focal segmental glomerulosclerosis	0.00115	0.021	CbGeAlD
Crizotinib—MET—kidney—focal segmental glomerulosclerosis	0.00104	0.0191	CbGeAlD
Crizotinib—ACVR1B—kidney—focal segmental glomerulosclerosis	0.000963	0.0177	CbGeAlD
Crizotinib—TESK1—nephron tubule—focal segmental glomerulosclerosis	0.000876	0.0161	CbGeAlD
Crizotinib—NUAK2—nephron tubule—focal segmental glomerulosclerosis	0.000831	0.0153	CbGeAlD
Crizotinib—FER—cortex of kidney—focal segmental glomerulosclerosis	0.00083	0.0152	CbGeAlD
Crizotinib—ACVR1—nephron tubule—focal segmental glomerulosclerosis	0.000825	0.0151	CbGeAlD
Crizotinib—IGF1R—kidney—focal segmental glomerulosclerosis	0.000819	0.015	CbGeAlD
Crizotinib—Burning sensation—Cyclosporine—focal segmental glomerulosclerosis	0.000789	0.0438	CcSEcCtD
Crizotinib—AURKA—kidney—focal segmental glomerulosclerosis	0.000776	0.0143	CbGeAlD
Crizotinib—STK3—cortex of kidney—focal segmental glomerulosclerosis	0.000776	0.0143	CbGeAlD
Crizotinib—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.000774	0.043	CcSEcCtD
Crizotinib—TESK1—cortex of kidney—focal segmental glomerulosclerosis	0.00075	0.0138	CbGeAlD
Crizotinib—RIPK2—nephron tubule—focal segmental glomerulosclerosis	0.000745	0.0137	CbGeAlD
Crizotinib—ACVR1—kidney—focal segmental glomerulosclerosis	0.000725	0.0133	CbGeAlD
Crizotinib—LIMK2—cortex of kidney—focal segmental glomerulosclerosis	0.000713	0.0131	CbGeAlD
Crizotinib—NUAK2—cortex of kidney—focal segmental glomerulosclerosis	0.000711	0.0131	CbGeAlD
Crizotinib—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.00071	0.0394	CcSEcCtD
Crizotinib—MAP3K2—nephron tubule—focal segmental glomerulosclerosis	0.000706	0.013	CbGeAlD
Crizotinib—ACVR1—cortex of kidney—focal segmental glomerulosclerosis	0.000706	0.013	CbGeAlD
Crizotinib—Abscess—Cyclosporine—focal segmental glomerulosclerosis	0.000693	0.0385	CcSEcCtD
Crizotinib—TBK1—nephron tubule—focal segmental glomerulosclerosis	0.000692	0.0127	CbGeAlD
Crizotinib—PTK2—nephron tubule—focal segmental glomerulosclerosis	0.000692	0.0127	CbGeAlD
Crizotinib—TYK2—nephron tubule—focal segmental glomerulosclerosis	0.000687	0.0126	CbGeAlD
Crizotinib—IRAK1—nephron tubule—focal segmental glomerulosclerosis	0.000678	0.0125	CbGeAlD
Crizotinib—PTK2B—kidney—focal segmental glomerulosclerosis	0.00066	0.0121	CbGeAlD
Crizotinib—SLK—nephron tubule—focal segmental glomerulosclerosis	0.000634	0.0116	CbGeAlD
Crizotinib—EPHB4—nephron tubule—focal segmental glomerulosclerosis	0.000629	0.0116	CbGeAlD
Crizotinib—EPHA2—nephron tubule—focal segmental glomerulosclerosis	0.000618	0.0113	CbGeAlD
Crizotinib—TBK1—kidney—focal segmental glomerulosclerosis	0.000608	0.0112	CbGeAlD
Crizotinib—PTK2—kidney—focal segmental glomerulosclerosis	0.000608	0.0112	CbGeAlD
Crizotinib—TYK2—kidney—focal segmental glomerulosclerosis	0.000604	0.0111	CbGeAlD
Crizotinib—MAP3K3—nephron tubule—focal segmental glomerulosclerosis	0.000602	0.0111	CbGeAlD
Crizotinib—PTK2—cortex of kidney—focal segmental glomerulosclerosis	0.000592	0.0109	CbGeAlD
Crizotinib—TBK1—cortex of kidney—focal segmental glomerulosclerosis	0.000592	0.0109	CbGeAlD
Crizotinib—TYK2—cortex of kidney—focal segmental glomerulosclerosis	0.000588	0.0108	CbGeAlD
Crizotinib—RPS6KB1—kidney—focal segmental glomerulosclerosis	0.000585	0.0107	CbGeAlD
Crizotinib—IRAK1—cortex of kidney—focal segmental glomerulosclerosis	0.00058	0.0107	CbGeAlD
Crizotinib—RPS6KB1—cortex of kidney—focal segmental glomerulosclerosis	0.000569	0.0105	CbGeAlD
Crizotinib—AXL—cortex of kidney—focal segmental glomerulosclerosis	0.000564	0.0104	CbGeAlD
Crizotinib—YES1—nephron tubule—focal segmental glomerulosclerosis	0.000556	0.0102	CbGeAlD
Crizotinib—EPHB4—kidney—focal segmental glomerulosclerosis	0.000553	0.0102	CbGeAlD
Crizotinib—JAK2—kidney—focal segmental glomerulosclerosis	0.000549	0.0101	CbGeAlD
Crizotinib—TAOK3—nephron tubule—focal segmental glomerulosclerosis	0.000549	0.0101	CbGeAlD
Crizotinib—SLK—cortex of kidney—focal segmental glomerulosclerosis	0.000543	0.00997	CbGeAlD
Crizotinib—EPHB4—cortex of kidney—focal segmental glomerulosclerosis	0.000539	0.0099	CbGeAlD
Crizotinib—JAK2—cortex of kidney—focal segmental glomerulosclerosis	0.000535	0.00983	CbGeAlD
Crizotinib—TEK—kidney—focal segmental glomerulosclerosis	0.000529	0.00972	CbGeAlD
Crizotinib—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.00052	0.0289	CcSEcCtD
Crizotinib—TEK—cortex of kidney—focal segmental glomerulosclerosis	0.000516	0.00947	CbGeAlD
Crizotinib—MAP3K3—cortex of kidney—focal segmental glomerulosclerosis	0.000516	0.00947	CbGeAlD
Crizotinib—MAP4K5—cortex of kidney—focal segmental glomerulosclerosis	0.000516	0.00947	CbGeAlD
Crizotinib—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.000515	0.0286	CcSEcCtD
Crizotinib—EPHB6—cortex of kidney—focal segmental glomerulosclerosis	0.000493	0.00905	CbGeAlD
Crizotinib—YES1—kidney—focal segmental glomerulosclerosis	0.000489	0.00898	CbGeAlD
Crizotinib—STK10—kidney—focal segmental glomerulosclerosis	0.000485	0.0089	CbGeAlD
Crizotinib—TAOK3—kidney—focal segmental glomerulosclerosis	0.000483	0.00887	CbGeAlD
Crizotinib—YES1—cortex of kidney—focal segmental glomerulosclerosis	0.000476	0.00875	CbGeAlD
Crizotinib—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.000476	0.0264	CcSEcCtD
Crizotinib—SRC—kidney—focal segmental glomerulosclerosis	0.00047	0.00864	CbGeAlD
Crizotinib—TAOK3—cortex of kidney—focal segmental glomerulosclerosis	0.00047	0.00863	CbGeAlD
Crizotinib—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000455	0.0253	CcSEcCtD
Crizotinib—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.000443	0.0246	CcSEcCtD
Crizotinib—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00042	0.0233	CcSEcCtD
Crizotinib—ABL1—nephron tubule—focal segmental glomerulosclerosis	0.00038	0.00698	CbGeAlD
Crizotinib—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.000351	0.0195	CcSEcCtD
Crizotinib—ABL1—kidney—focal segmental glomerulosclerosis	0.000334	0.00613	CbGeAlD
Crizotinib—ABL1—cortex of kidney—focal segmental glomerulosclerosis	0.000325	0.00597	CbGeAlD
Crizotinib—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00032	0.0178	CcSEcCtD
Crizotinib—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000311	0.0173	CcSEcCtD
Crizotinib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000308	0.0171	CcSEcCtD
Crizotinib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000307	0.017	CcSEcCtD
Crizotinib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000307	0.017	CcSEcCtD
Crizotinib—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.0003	0.0167	CcSEcCtD
Crizotinib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00029	0.0161	CcSEcCtD
Crizotinib—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000274	0.0152	CcSEcCtD
Crizotinib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000272	0.0151	CcSEcCtD
Crizotinib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00027	0.015	CcSEcCtD
Crizotinib—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000265	0.0147	CcSEcCtD
Crizotinib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000248	0.0138	CcSEcCtD
Crizotinib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000246	0.0137	CcSEcCtD
Crizotinib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00024	0.0133	CcSEcCtD
Crizotinib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000235	0.013	CcSEcCtD
Crizotinib—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000226	0.0125	CcSEcCtD
Crizotinib—CYP3A5—nephron tubule—focal segmental glomerulosclerosis	0.000222	0.00408	CbGeAlD
Crizotinib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000221	0.0123	CcSEcCtD
Crizotinib—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000214	0.0119	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000203	0.0113	CcSEcCtD
Crizotinib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000196	0.0109	CcSEcCtD
Crizotinib—CYP3A5—kidney—focal segmental glomerulosclerosis	0.000195	0.00359	CbGeAlD
Crizotinib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000194	0.0108	CcSEcCtD
Crizotinib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000192	0.0107	CcSEcCtD
Crizotinib—CYP3A5—cortex of kidney—focal segmental glomerulosclerosis	0.00019	0.0035	CbGeAlD
Crizotinib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00019	0.0106	CcSEcCtD
Crizotinib—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000176	0.00976	CcSEcCtD
Crizotinib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000174	0.00969	CcSEcCtD
Crizotinib—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000172	0.00957	CcSEcCtD
Crizotinib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00017	0.00945	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000169	0.00938	CcSEcCtD
Crizotinib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000169	0.00937	CcSEcCtD
Crizotinib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000167	0.00929	CcSEcCtD
Crizotinib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000155	0.00859	CcSEcCtD
Crizotinib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000147	0.00269	CbGeAlD
Crizotinib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00014	0.0078	CcSEcCtD
Crizotinib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000134	0.00744	CcSEcCtD
Crizotinib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000129	0.00719	CcSEcCtD
Crizotinib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000124	0.00691	CcSEcCtD
Crizotinib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000123	0.00685	CcSEcCtD
Crizotinib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000123	0.00685	CcSEcCtD
Crizotinib—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.000118	0.00217	CbGeAlD
Crizotinib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000116	0.00645	CcSEcCtD
Crizotinib—ABCB1—kidney—focal segmental glomerulosclerosis	0.000104	0.00191	CbGeAlD
Crizotinib—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000101	0.00186	CbGeAlD
Crizotinib—NTRK1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	5.5e-06	4.59e-05	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—MMP9—focal segmental glomerulosclerosis	5.5e-06	4.59e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.47e-06	4.56e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.47e-06	4.56e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	5.43e-06	4.53e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	5.41e-06	4.52e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	5.4e-06	4.51e-05	CbGpPWpGaD
Crizotinib—LCK—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	5.39e-06	4.5e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD40LG—focal segmental glomerulosclerosis	5.38e-06	4.49e-05	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.38e-06	4.49e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.38e-06	4.49e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	5.37e-06	4.48e-05	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	5.36e-06	4.47e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—ALB—focal segmental glomerulosclerosis	5.36e-06	4.47e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD79A—focal segmental glomerulosclerosis	5.35e-06	4.46e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	5.34e-06	4.46e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—ALB—focal segmental glomerulosclerosis	5.33e-06	4.45e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	5.33e-06	4.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	5.33e-06	4.45e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD79A—focal segmental glomerulosclerosis	5.32e-06	4.44e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—FN1—focal segmental glomerulosclerosis	5.29e-06	4.41e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—NOS2—focal segmental glomerulosclerosis	5.23e-06	4.36e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—MMP2—focal segmental glomerulosclerosis	5.22e-06	4.35e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	5.22e-06	4.35e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.19e-06	4.33e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—MMP9—focal segmental glomerulosclerosis	5.18e-06	4.32e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	5.14e-06	4.29e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.1e-06	4.25e-05	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	5.09e-06	4.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	5.02e-06	4.19e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—ALB—focal segmental glomerulosclerosis	5.02e-06	4.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD79A—focal segmental glomerulosclerosis	5.01e-06	4.18e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	5e-06	4.17e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	4.98e-06	4.15e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	4.95e-06	4.13e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	4.94e-06	4.12e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.93e-06	4.12e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	4.9e-06	4.09e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.9e-06	4.08e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—LPL—focal segmental glomerulosclerosis	4.88e-06	4.07e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	4.87e-06	4.06e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	4.82e-06	4.02e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.8e-06	4e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.79e-06	4e-05	CbGpPWpGaD
Crizotinib—SRC—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	4.77e-06	3.98e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.74e-06	3.96e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.73e-06	3.94e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—SERPINE1—focal segmental glomerulosclerosis	4.72e-06	3.94e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	4.7e-06	3.92e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—FN1—focal segmental glomerulosclerosis	4.68e-06	3.91e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.68e-06	3.9e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	4.66e-06	3.89e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	4.63e-06	3.87e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—NOS2—focal segmental glomerulosclerosis	4.63e-06	3.86e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TGFB1—focal segmental glomerulosclerosis	4.61e-06	3.85e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.6e-06	3.84e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.58e-06	3.82e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	4.55e-06	3.79e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.54e-06	3.79e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.54e-06	3.79e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.52e-06	3.77e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	4.52e-06	3.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	4.52e-06	3.77e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.51e-06	3.76e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.51e-06	3.76e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.51e-06	3.76e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.48e-06	3.73e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	4.4e-06	3.67e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.4e-06	3.67e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—ALB—focal segmental glomerulosclerosis	4.39e-06	3.66e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.39e-06	3.66e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD79A—focal segmental glomerulosclerosis	4.38e-06	3.66e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.38e-06	3.65e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD40LG—focal segmental glomerulosclerosis	4.36e-06	3.64e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	4.34e-06	3.62e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD40LG—focal segmental glomerulosclerosis	4.34e-06	3.62e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.28e-06	3.57e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.28e-06	3.57e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.27e-06	3.57e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	4.27e-06	3.56e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—MMP9—focal segmental glomerulosclerosis	4.26e-06	3.56e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.25e-06	3.55e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—MMP9—focal segmental glomerulosclerosis	4.19e-06	3.5e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	4.17e-06	3.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.15e-06	3.47e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.15e-06	3.47e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.15e-06	3.46e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	4.13e-06	3.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.12e-06	3.44e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.1e-06	3.42e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.09e-06	3.42e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD40LG—focal segmental glomerulosclerosis	4.08e-06	3.4e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MMP2—focal segmental glomerulosclerosis	4.05e-06	3.38e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.04e-06	3.37e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.92e-06	3.27e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.91e-06	3.26e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	3.9e-06	3.25e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—ALB—focal segmental glomerulosclerosis	3.89e-06	3.24e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD79A—focal segmental glomerulosclerosis	3.88e-06	3.24e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.88e-06	3.24e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.87e-06	3.23e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.83e-06	3.19e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NOS2—focal segmental glomerulosclerosis	3.81e-06	3.18e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.79e-06	3.16e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.76e-06	3.14e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.75e-06	3.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	3.75e-06	3.13e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.75e-06	3.13e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.74e-06	3.12e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.71e-06	3.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—LPL—focal segmental glomerulosclerosis	3.7e-06	3.09e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.68e-06	3.07e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.67e-06	3.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.63e-06	3.03e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.61e-06	3.01e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.59e-06	2.99e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.58e-06	2.98e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD40LG—focal segmental glomerulosclerosis	3.57e-06	2.98e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.56e-06	2.97e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.54e-06	2.95e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.52e-06	2.94e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.52e-06	2.94e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.52e-06	2.93e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.47e-06	2.89e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	3.46e-06	2.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.44e-06	2.87e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	3.44e-06	2.87e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.42e-06	2.85e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.42e-06	2.85e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TGFB1—focal segmental glomerulosclerosis	3.39e-06	2.83e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	3.37e-06	2.81e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.36e-06	2.81e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.33e-06	2.78e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—LPL—focal segmental glomerulosclerosis	3.24e-06	2.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.24e-06	2.7e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	3.23e-06	2.7e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.22e-06	2.69e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—SERPINE1—focal segmental glomerulosclerosis	3.21e-06	2.68e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.19e-06	2.66e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.18e-06	2.65e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.17e-06	2.65e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	3.17e-06	2.65e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TGFB1—focal segmental glomerulosclerosis	3.17e-06	2.65e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD40LG—focal segmental glomerulosclerosis	3.16e-06	2.64e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.15e-06	2.63e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.15e-06	2.63e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.11e-06	2.59e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.09e-06	2.58e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	3.09e-06	2.57e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.04e-06	2.54e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.02e-06	2.52e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.02e-06	2.52e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.01e-06	2.51e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—TGFB1—focal segmental glomerulosclerosis	2.98e-06	2.49e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.98e-06	2.48e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.97e-06	2.48e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.93e-06	2.45e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.92e-06	2.44e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS2—focal segmental glomerulosclerosis	2.89e-06	2.41e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.89e-06	2.41e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—LPL—focal segmental glomerulosclerosis	2.87e-06	2.39e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.85e-06	2.38e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.78e-06	2.32e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.78e-06	2.32e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.77e-06	2.31e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.76e-06	2.3e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	2.72e-06	2.27e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.71e-06	2.26e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.7e-06	2.25e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.67e-06	2.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.67e-06	2.23e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.62e-06	2.19e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.59e-06	2.16e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS2—focal segmental glomerulosclerosis	2.53e-06	2.11e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.51e-06	2.09e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.5e-06	2.09e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.48e-06	2.07e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.46e-06	2.05e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.45e-06	2.05e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.44e-06	2.04e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.44e-06	2.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—SERPINE1—focal segmental glomerulosclerosis	2.43e-06	2.03e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.42e-06	2.02e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.38e-06	1.99e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.37e-06	1.98e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.34e-06	1.95e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	2.33e-06	1.94e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.32e-06	1.93e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.28e-06	1.9e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.27e-06	1.89e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.25e-06	1.88e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS2—focal segmental glomerulosclerosis	2.24e-06	1.87e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.23e-06	1.86e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.22e-06	1.85e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.21e-06	1.84e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.19e-06	1.83e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.15e-06	1.79e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—SERPINE1—focal segmental glomerulosclerosis	2.13e-06	1.78e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.07e-06	1.73e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	2.05e-06	1.71e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.05e-06	1.71e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—focal segmental glomerulosclerosis	2.03e-06	1.69e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.01e-06	1.68e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.99e-06	1.66e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.99e-06	1.66e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.96e-06	1.64e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.94e-06	1.62e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.9e-06	1.59e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.9e-06	1.58e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.89e-06	1.58e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—SERPINE1—focal segmental glomerulosclerosis	1.89e-06	1.57e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	1.88e-06	1.57e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.88e-06	1.57e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.87e-06	1.56e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.82e-06	1.52e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.82e-06	1.52e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.79e-06	1.5e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.77e-06	1.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.72e-06	1.44e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.72e-06	1.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.7e-06	1.42e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	1.61e-06	1.34e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.59e-06	1.32e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.56e-06	1.3e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.54e-06	1.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—focal segmental glomerulosclerosis	1.54e-06	1.28e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.49e-06	1.24e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.46e-06	1.22e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	1.43e-06	1.2e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	1.42e-06	1.19e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.42e-06	1.18e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.39e-06	1.16e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—focal segmental glomerulosclerosis	1.35e-06	1.12e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.32e-06	1.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.3e-06	1.09e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	1.26e-06	1.05e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	1.24e-06	1.03e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	1.22e-06	1.01e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—focal segmental glomerulosclerosis	1.19e-06	9.93e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.16e-06	9.71e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.15e-06	9.59e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.14e-06	9.53e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.08e-06	8.97e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.01e-06	8.44e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.42e-07	7.86e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	9.33e-07	7.78e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	8.75e-07	7.3e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.34e-07	6.96e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	7.49e-07	6.25e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	5.75e-07	4.79e-06	CbGpPWpGaD
